Nicotine: Pharmacology, toxicity and therapeutic use

Journal of Smoking Cessation

Volumn 9, Issue 2, 2013, Pages 53-59

  Fagerström, Karl ^a  

^a Smoker's Information Centre   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84988248542     PISSN: None     EISSN: 18342612     Source Type: Journal    
DOI: 10.1017/jsc.2014.27     Document Type: Article

References (72)

1. Anfang, M. K., & Pope, H. Jr. (1997). Treatment of neuroleptically-induced akathisiawith nicotine patches. Psychopharmacology, 134, 153-156.
2. ASH (Action on Smoking, Health) (2007). Nicotine replacement therapy guidelines for healthcare professionals on using nicotine replacement therapy for smokers not yet ready to stop smoking. (17 pp.). ASH (Action on Smoking,Health) (2012). E-cigarette use in Great Britain: 2010 and 2012.
3. Baba, S., Wikstrom, A. K., Stephansson, O., & Cnattingius, S. (2013). Changes in snuff and smoking habits in Swedish pregnant women and risk for small for gestational age births. BJOG: An International Journal of Obstetrics & Gynaecology, 120(4), 456-462. doi: 10.1111/1471-0528.12067. Epub 2012 Nov 27
4. Barr, R. S.,Culhane,M. A., Jubelt, L. E.,Mufti, R. S.,Dyer, M. A., Weiss, A. P. et al. (2008). The effects of transdermal nicotine on cognition in nonsmokers with schizophrenia and nonpsychiatric controls. Neuropsychopharmacology, 33(3), 480-490. Epub 2007 Apr 18.
5. Barrett, S. P. (2010). The effects of nicotine, denicotinized tobacco, and nicotine-containing tobacco on cigarette craving, withdrawal, and self-Administration in male and female smokers. Behavioural Pharmacology, 21, 144-152. doi:10.1097/FBP.0b013e328337be68.
6. Baum, S. S., Hill, R., & Rommelspacher, H. (1996). Harmaninduced changes of extracellular concentrations of neurotransmitters in the nucleus accumbens of rats. European Journal of Pharmacology, 314, 75-82. doi:10.1016/S0014- 2999(96)00543-2.
7. Beard, E., McDermott, M., McEwen, A., & West, R. (2012). Beliefs of stop smoking practitioners in United Kingdom on the use of nicotine replacement therapy for smoking reduction. Nicotine & Tobacco Research, 14(1469-994X (Electronic)), 639-647. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22180579. Accessed October 10, 2012.
8. Benowitz, N. L., Hansson, A., & Jacob, P. I. (2002). Cardiovascular effects of nasal and transdermal nicotine and cigarette smoking. Hypertension, 39(1524-4563 (Electronic)), 1107-1112.
9. Benwell, M. E. M., Balfour, D., & Birrell, C. E. (1995). Desensitization of nicotine-induced mesolimbic dopamine response during constant infusion with nicotine. British Journal of Pharmacology, 114, 454-460.
10. Brennan, K. A., Crowther, A., Putt, F., Roper, V., Waterhouse, U., & Truman, P. (2013). Tobacco particulate matter selfadministration in rats: Differential effects of tobacco type. Add Biology, doi:10.1111/adb.12099.
11. Brody, A. L., Mandelkern, M. A., Costello, M. R., Abrams, A. L., Scheibal, D., Farahi, J. et al. (2009). Brain nicotinic acetylcholine receptor occupancy effect of smoking a denicotinized cigarette. International Journal of Neuropsychopharmacology, 12, 305-316. doi:10.1017/S146114570800922X.
12. Buchhalter, A. R., Acosta, M. C., Evans, S. E., Breland, B., & Eissenberg, T. (2005). Tobacco abstinence symptom suppression: The role played by the smoking-related stimuli that are delivered by denicotinized cigarettes. Addiction, 100, 550-559. doi:10.1111/j.1360-0443.2005.01030.x.
13. Chaudhri, N.,Caggiula,A. R., Donny, E. C., Palmatier,M. I., Liu, X.,&Sved, A. F. (2006). Complex interactions between nicotine and nonpharmacological stimuli reveal multiple roles for nicotine in reinforcement. Psychopharmacology (Berl), Mar, 184(3-4), 353-366. Epub 2005 Oct 21. Review.
14. Chen, R .J., Ho, Y. S., Guo, H. R., & Wang, Y. J. (2008b). Rapid activation of Stat3 and ERK1/2 by nicotine modulates cell proliferation in human bladder cancer cells. Toxicological Sciences, 104(2), 283-293.
15. Clemens, K. J., Cailille, S., Stinus, L., & Cador, M. (2009). The addition of five minor tobacco alkaloids increases nicotineinduced hyperactivity, sensitization and intravenous selfadministration in rats. International Journal of Psychopharmacology, 12, 1355-1366. doi:10.1017/S1461145709000273.
16. Cosgrove, K. P., Batis, J., Bois, F., Maciejewski, P. K., Esterlis, I., Kloczynski, T. et al. (2009). 2-Nicotinic acetylcholine receptor availability during acute and prolonged abstinence from tobacco smoking. Archives of General Psychiatry, 66(6), 666-676.
17. Cummings, K. M., Hyland, A., Giovino, G. A., Hastrup, J. L., Bauer, J. E., & Bansal, M.A. (2004). Are smokers adequately informed about the health risks of smoking and medicinal nicotine? Nicotine & Tobacco Research, 6 Suppl 3(December), S333-S340. Available at: http://www.ncbi.nlm.nih.gov/pubmed/15799596.
18. Dale, L. C., Hurt, R. D., Offord, K. P., Lawson, G. M., Croghan, I. T., & Schroeder, D. R. (1995). High-dose nicotine patch therapy. Percentage of replacement and smoking cessation. Journal of the AmericanMedical Association, 274, 1353-1358. doi:10.1001/jama.1995.0353017003.
19. DiFranza, J., & Ursprung, W.W. (2010). A systematic review of the international classification of diseases criteria for the diagnosis of tobacco dependence. Addictive Behaviors, 35, 805-810. doi:10.1016/j.addbeh.2010.04.002. EU Barometer 385. Available at: http://ec.europa.eu/public-opinion/index-en.htm.
20. Fagerstrom, K., & Eissenberg, T. (2012). Dependence on tobacco and nicotine products: A case for product-specific assessment. Nicotine & Tobacco Research, 14, 1382-1390. doi: 10.1093/ntr/nts007.
21. Fagerstrom, K. O., & Pomerleau,O. (1994).Nicotinemay relieve symptoms of parkinsons disease. Psychopharmacology, 116, 117-119.
22. Fiore, M.C., Jaen, C.R., Baker, T.B., Bailey, W.C., Benowitz, N., Curry, S.J. et al. (2008). Treating tobacco use and dependence: 2008 update. Rockville, MD: U.S. Department of Health and Human Services. Retrieved from http://www.ahrq.gov/path/tobacco.htm#Clinic.
23. Fiore, M. C., Schroeder, S. A., & Baker, T. B. (2014). Smoke, the chief killer - strategies for targeting combustible Tobacco use. New England Journal ofMedicine, 370, 297-299. January 23, 2014, doi: 10.1056/NEJMp1314942.
24. Fowler, J. S.,Logan, J.,Wang,G. J.,Volkow,N. D.,Telang, F.,Zhu, W. et al. (2003). Low monoamine oxidase B in peripheral organs in smokers. Proceedings of the National Academy of Sciences of the United States of America, 30, 11600-11605. doi:10.1073/pnas.1833106100.
25. Fowler, J.S., Wang, G. J., Volkow, N. D., Franceschi, D., Logan, J., Pappas, N. et al. (1999). Smoking a single cigarette does not produce a measurable reduction in brain MAO B in non-smokers. Nicotine & Tobacco Research, 1, 325-329. doi:10.1080/14622299050011451.
26. Gehricke, J. G., Hong, N., Whalen, C. K., Steinhoff, K., & Wigal, T. L. (2009). Effects of transdermal nicotine on symptoms, moods, and cardiovascular activity in the everyday lives of smokers and nonsmokers with attentiondeficit/hyperactivity disorder. Psychology of Addictive Behaviors, Dec, 23(4), 644-655. doi: 10.1037/a0017441.
27. Green, J.T., Thomas, G.A., Rhodes, J., Williams, G.T., Evans, B.K., Russell, M.A. et al. (1997). Nicotine enemas for active ulcerative colitis-A pilot study. Alimentary Pharmacology & Therapeutics, Oct, 11(5), 859-863.
28. Greenland, S., Satterfield, M. H., & Lanes, S. F. (1998). A meta-Analysis to assess the incidence of adverse effects associated with the transdermal nicotine patch. Drug Safety: An International Journal of Medical Toxicology and Drug Experience, 18(4), 297-308. Available at: http://www.ncbi.nlm.nih.gov/pubmed/9565740. Accessed October 10, 2012.
29. Hansson, J., Galanti, M. R., Hergens, M.-P., Fredlund, P., Ahlbom,A., Alfredsson, L. et al. (2012).Use of snus and acute myocardial infarction: Pooled analysis of eight prospective observational studies. European Journal of Epidemiology,Oct, 27(10), 771-779. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22722951. Accessed October 9, 2012.
30. Hedstrom, A. K., Hillert, J., Olsson, T., & Alfredsson, T. (2013). Nicotine might have a neuroprotective effect in the etiology ofmultiple sclerosis.Multiple Sclerosis, Jul, 19(8), 1009-1013. doi: 10.1177/1352458512471879. Epub 2013 Jan 14.
31. Hergens, M. P., Alfredsson, L., Bolinder, G., Lambe, M., Pershagen, G., & Ye, W. (2007). Long-term use of Swedish moist snuff and the risk of myocardial infarction amongst men. Journal of Internal Medicine, 262(0954-6820 (Print)), 351-359.
32. Hubbard, R., Lewis, S., Smith, C., Godfrey, C., Smeeth, L., Farrington, P. et al. (2005). Use of nicotine replacement therapy and the risk of acute myocardial infarction, stroke, and death. Tobacco Control, 14(6), 416-421. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi? artid=1748112&tool=pmcentrez&rendertype=abstract. Accessed October 9, 2012.
33. Hughes, J. R.,Rose,G. L.,&Callas,P .W. (2000).Nicotine ismore reinforcing in smokers with a past history of alcoholism than in smokers without this history. Alcoholism: Clinical and Experimental Research, 24, 1633-1638. doi:10.1111/j.1530- 0277.2000.tb01964.x.
34. International Agency for Research on Cancer (2004). Tobacco smoke and involuntary smoking. IACR Monograph, Volume 83. Lyon; 2004, 1452 pp. Available at: http://monographs.iarc.fr/ENG/Monographs/vol83/index.php.
35. International Agency for Research on Cancer (2007). Some tobacco-specific N-nitrosamines. IACRMonograph, Volume 89, 583.
36. Jacob, P. 3rd, Benowitz, N. L., & Shulgin, A. T. (1988). Recent studies of nicotine metabolism in humans. Pharmacology Biochemistry Behavior, 30(1), 249-253.
37. Joseph, A., Norman, S., Ferry, L., Prochazka, A.V., Westman, E. C., Steele, B. G. et al. (1996). The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease. The New England Journal of Medicine, 335, 1792-1798.
38. Kimmel, S. E., Berlin, J. A., Miles, C., Jaskowiak, J., Carson, J. L., & Strom, B. L. (2001). Risk of acute first myocardial infarction and use of nicotine patches in a general population. Journal of the American College of Cardiology, 37(5), 1297-1302. Available at: http://www.ncbi.nlm.nih.gov/pubmed/11300438.
39. Kloosterman, K. (2013). Electronic cigarette kills toddler in Israel. Green Prophet, 29 May. 2013. Available at: http://www.greenprophet.com/2013/05/electroniccigarette- kills-toddler-in-israel/(accessed 4 April 2014) (Archived at http://www.webcitation.org/6QnAb1lS9 on 3 July 2014
40. Lee, J., & Cooke, J. P. (2012). Nicotine and pathological angiogenesis. Life Sciences, 91(21-22), 1058-1064.
41. Lee, P. N. (2007). Circulatory disease and smokeless tobacco in Western populations: A review of the evidence. International Journal of Epidemiology, 36(4), 789-804. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17591642. Accessed October 9, 2012.
42. Lee, P. N. (2011). Summary of the epidemiological evidence relating snus to health. Regulatory Toxicology and Pharmacology, 59(1096-0295 (Electronic)), 197-214.
43. Lewin, F., Norell, S. E., Johansson, H. et al. (1998). Smoking tobacco, oral snuff, and alcohol in the etiology of squamous cell carcinoma of the head and neck: A population-based casereferent study in Sweden. Cancer, 82(7), 1367-1375. Available at: http://www.ncbi.nlm.nih.gov/pubmed/9529030. Accessed February 11, 2013.
44. Lopez, A. D., Christopher, J. L., Murray, M. D., Gakidou, E., Mathers, C. D., Ezzati, M. et al. (2006). Global burden of disease and risk factors. Washington DC: The World Bank Group and New York: Oxford University Press, 2006. www.dcp2.org/pubs/GBD (accessed 7 August 2007
45. Lunell, E., & Lunell, M. (2005). Steady-state nicotine plasma levels following use of four different types of Swedish snus compared with 2-mg Nicorette chewing gum: A crossover study. Nicotine & Tobacco Research,, 7(3), 397-403.
46. Luo, J., Ye,W., Zendehdel, K., Adami, J., Adami, H. O., Boffetta, P. et al. (2007). Oral use of Swedish moist snuff (snus) and risk for cancer of the mouth, lung, and pancreas in male construction workers: A retrospective cohort study. Lancet, 369(1474-547X (Electronic)), 2015-2020.
47. McClernon, F. J., Hiott, F. B., Westman, E. C., Rosse, J. E., & Levin, E. D. (2006). Transdermal nicotine attenuates depression symptoms in non-smokers: A double blind, placebo controlled trial. Psychopharmacology, 189, 125-133.
48. Meyer, B. (2013). How much nicotine kills a human? Tracing back the generally accepted lethal dose to dubious selfexperiments in the nineteenth century. Archives of Toxicology, 88, 5-7. 10.1007/s00204-013-1127-0.
49. Murray, R. P., Connett, J. E., & Zapawa, L. M. (2009). Does nicotine replacement therapy cause cancer? Evidence from the Lung Health Study. Nicotine & Tobacco Research: Official journal of the Society for Research on Nicotine and Tobacco, 11(9), 1076-1082. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi? artid=2725009&tool=pmcentrez&rendertype=abstract. Accessed October 9, 2012.
50. Newhouse, P., Kellar, K., Aisen, P., White, H., Wesnes, K., Coderre, E. et al. (2012). Nicotine treatment of mild cognitive impairment: A 6-month double-blind pilot clinical trial. Neurology, Jan 10, 78(2), 91-101. doi: 10.1212/WNL.0b013e31823efcbb.
51. Ng, M., Freeman, M. K., Fleming, T. D., Robinson, M., Dwyer- Lindgren, L., Thomson, B. et al. (2014). Smoking prevalence and cigarette consumption in 187 countries, 1980-2012. Journal of American Medical Association, 311(2), 183-192. doi:10.1001/jama.2013.284692.
52. OReilly, E. J., McCullough, M. L., Chao, A., Henley, S. J., Calle, E. E., Thun, M. J. et al. (2005). Smokeless tobacco use and the risk of Parkinsons disease mortality. Movement Disorders, 20(10), 1383-1384.
53. Pauly, J. R., & Slotkin, T. A. (2008). Maternal tobacco smoking, nicotine replacement and neurobehavioural development. Acta Paediatrica, 97(10), 1331-1337. doi: 10.1111/j.1651- 2227.2008.00852.x. Epub 2008 Jun 12.
54. Perkins, K. A. (1993).Weight gain following smoking cessation. Journal of Consulting and Clinical Psychology, 61, 768-777.
55. Perkins, K.A., Gerlach, D., Broge, M., Fonte, C., & Wilson, A. (2001). Reinforcing effects of nicotine as a function of smoking status. Experimental and Clinical Pharmacology, 9, 243-250. doi:10.1037/1064-1297.9.3.243.
56. Peto, R., Lopez, A. D., Boreham, J., Thun, M., Heath, C. Jr., & Doll, R. (1996). Mortality from smoking worldwide. British Medical Bulletin, 52(1), 12-21.
57. Rodd, Z. A., Bell, R. L., Zhang, Y., Goldstein, A., Zaffaroni, A., McBride, W. J. et al. (2003). Salsolinol produces reinforcing effects in the nucleus accumbens shell of alcohol-preferring (P)rats. Alcoholism Clinical and Experimental Research, 27, 440-449. doi:10.1097/01.ALC.0000056612.89957.B4.
58. Sandborn,W. J. (1999). Nicotine therapy for ulcerative colitis: A review of rationale, mechanisms, pharmacology, and clinical results. The American Journal of Gastroenterology, 94(5), 1161-1171. Review.
59. Schildt, E. B., Eriksson, M., Hardell, L., & Magnuson, A. (1998). Oral snuff, smoking habits and alcohol consumption in relation to oral cancer in a Swedish casecontrol study. International Journal of Cancer. Journal International du Cancer, 77(3), 341-346. Available at: http://www.ncbi.nlm.nih.gov/pubmed/9663593. Accessed February 11, 2013.
60. Sherwood,N. (1993). Effects of nicotine on human psychomotor performance. Human Psychopharmacology, 8, 155-184.
61. Sieber, M. (2012). Neuroprotective properties of nicotine. Current Medicinal Chemistry, 19(2), 292-297.
62. Silver, A. A., Shytle, R. D., Philipp, M. K., Wilkinson, B. J., McConville, B., & Sanberg, P. R. (2001). Transdermal nicotine and haloperidol in Tourettes disorder: A doubleblind placebo-controlled study. Journal ofClinical Psychiatry, 62(9), 707-714.
63. Thiriez, C., Villafane, G., Grapin, F., Fenelon, G., Remy, P., & Cesaro, P. (2011). Can nicotine be used medicinally in Parkinsons disease? Expert Review of Clinical Pharmacology, Jul, 4(4), 429-436. doi: 10.1586/ecp.11.27. Review.
64. Ulrich, Y.M., Hargreaves, K.M., & Flores, C.M. (1997). A comparison of multiple injections versus continuous infusion of nicotine for producing up-regulation of neuronal [3H]- epibatidine binding sites. Neuropharmacology, 36, 1119-1125.
65. US Department of Health and Human Services (1988). The health consequences of smoking. Nicotine addiction: A Report of the Surgeon-General. Rockville, MD: Author.
66. US Department of Health and Human Services (2014). The health consequences of smoking-50 years of progress. A Report of the Surgeon General. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2014. Printed with corrections, January 2014.
67. Villegier, A. S., Blanc, G., Glowinski, J., & Tassin, J. P. (2003). Transient behavioural sensitization to nicotine becomes long lasting with monoamine oxidase inhibitors. Pharmacology Biochemistry & Behaviour, 76, 267-274. doi:10.1016/S0091- 3057(03)00223-5.
68. Wikstrom, A. K., Cnattingius, S., & Stephansson, O. (2010a). Maternal use of Swedish snuff (snus) and risk of stillbirth. Epidemiology, 21(1531-5487 (Electronic)), 772-778.
69. Wikstrom, A. K., Stephansson, O., & Cnattingius, S. (2010b). Tobacco use during pregnancy and preeclampsia risk: Effects of cigarette smoking and snuff. Hypertension, 55(1524-4563 (Electronic)), 1254-1259.
70. Wilbert, J. (1993). Tobacco and Shamanism in South America ISBN 0-300-05790-3.
71. Wolf, R., Orion, E., Matz, H., Maitra, S., & Rowland-Payne, C. (2004). Smoking can be good for you. Journal of Cosmetic Dermatology, 3(2), 107-111.
72. Zendehdel, K., Nyren, O., Luo, J., Dickman, P.W., Boffetta, P., Englund, A. et al. (2008). Risk of gastroesophageal cancer among smokers and users of Scandinavian moist snuff. International Journal of Cancer, 122(1097-0215 (Electronic)), 1095-1099.